



The BMJ

pdoshi@bmj.com

Cite this as: *BMJ* 2020;371:m4037<http://dx.doi.org/10.1136/bmj.m4037>

Published: 21 October 2020

Will covid-19 vaccines save lives? Current trials aren't designed to tell us

The world has bet the farm on vaccines as the solution to the pandemic, but the trials are not focused on answering the questions many might assume they are. **Peter Doshi** reports

Peter Doshi *associate editor*

As phase III trials of covid-19 vaccines reach their target enrolments, officials have been trying to project calm. The US coronavirus czar Anthony Fauci and the Food and Drug Administration leadership have offered public assurances that established procedures will be followed.¹⁻⁴ Only a “safe and effective” vaccine will be approved, they say, and nine vaccine manufacturers issued a rare joint statement pledging not to prematurely seek regulatory review.⁵

But what will it mean exactly when a vaccine is declared “effective”? To the public this seems fairly obvious. “The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying,” a National Public Radio broadcast said bluntly.⁶

Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, “Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission.”⁷

Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.

Table 1 | Characteristics of ongoing phase III covid-19 vaccine trials

	Moderna	Pfizer	AstraZeneca (US)	AstraZeneca (UK)	Janssen	Sinopharm*	Sinovac
Vaccine name	mRNA-1273	BNT162	AZD1222	AZD1222	Ad26.COV2.S	Sinopharm vaccine	Sinovac CoronaVac
Registration No	NCT04470427	NCT04368728	NCT04516746	NCT04400838 (UK), NCT04536051 (Brazil), NCT04444674 (South Africa)	NCT04505722	NCT04510207	NCT04456595
Target enrolment	30 000	43 998	30 000	19 330	60 000	45 000	8870
Ages eligible	18+	12+	18+	5-12, 18+	18+	18+	18+
Protocol publicly available	Y	Y	Y	N†	Y	N	N
Notable excluded populations:							
Children and adolescents	Excluded	Many excluded	Excluded	13-17 excluded	Excluded	Excluded	Excluded
Immunocompromised patients	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
Pregnant or breastfeeding women	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
Endpoints undergoing formal study‡:							
Prevention of symptomatic disease in vaccine recipient	Y	Y	Y	Y	Y	Presumably§	Y
Reduction in severe covid-19 (hospital admission, ICU, or death)	N	N	N	N¶	N	N	N
Interruption of transmission (person to person spread)	N	N	N	N	N	N	N

* This trial is separately randomising an inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by Wuhan Institute of Biological Products Co and Beijing Institute of Biological Products Co.

† AstraZeneca has released the protocol for its stalled US trial but not its trial in UK, Brazil, and South Africa.

‡ Endpoints "undergoing formal study" include those listed as primary outcomes in ClinicalTrials.gov, publicly available study protocols, or those not listed as primary outcomes, but the company has confirmed that the study is powered sufficiently to find an effect (if one exists).

§ Sinopharm lists "incidence of COVID-19 cases" as a primary efficacy endpoint in its ClinicalTrials.gov entry.

¶ Trial registration (NCT04444674) lists the following primary endpoint: "Determine if there is a reduction of severe and non-severe COVID-19 disease in HIV-negative adults." This suggests a composite outcome that includes non-severe disease.

Evaluating mild, not severe, disease

In a September interview Medscape editor in chief Eric Topol pondered what counts as a recorded "event" in the vaccine trials. "We're not talking about just a PCR [polymerase chain reaction test]-positive mild infection. It has to be moderate to severe illness to qualify as an event, correct?" he asked.⁸

"That's right," concurred his guest, Paul Offit, a vaccinologist who sits on the FDA advisory committee that may ultimately recommend the vaccines for licence or emergency use authorisation.

But that's not right. In all the ongoing phase III trials for which details have been released, laboratory confirmed infections even with only mild symptoms qualify as meeting the primary endpoint definition.⁹⁻¹² In Pfizer and Moderna's trials, for example, people with only a cough and positive laboratory test would bring those trials one event closer to their completion. (If AstraZeneca's ongoing UK trial is designed similarly to its "paused" US trial for which the company has released details, a cough and fever with positive PCR test would suffice.)

Part of the reason may be numbers. Severe illness requiring hospital admission, which happens in only a small fraction of symptomatic covid-19 cases, would be unlikely to occur in significant numbers

in trials. Data published by the US Centers for Disease Control and Prevention in late April reported a symptomatic case hospitalisation ratio of 3.4% overall, varying from 1.7% in 0-49 year olds and 4.5% in 50-64 year olds to 7.4% in those 65 and over.¹³ Because most people with symptomatic covid-19 experience only mild symptoms,¹⁴ even trials involving 30 000 or more patients would turn up relatively few cases of severe disease.

In the trials, final efficacy analyses are planned after just 150 to 160 "events,"—that is, a positive indication of symptomatic covid-19, regardless of severity of the illness.

Yet until vaccine manufacturers began to release their study protocols in mid-September, trial registries and other publicly released information did little to dispel the notion that it was severe covid-19 that the trials were assessing. Moderna, for example, called hospital admissions a "key secondary endpoint" in statements to the media.¹⁵ And a press release from the US National Institutes of Health reinforced this impression, stating that Moderna's trial "aims to study whether the vaccine can prevent severe covid-19" and "seeks to answer if the vaccine can prevent death caused by covid-19."¹⁶

But Tal Zaks, chief medical officer at Moderna, told *The BMJ* that the company's trial lacks adequate statistical power to assess those

outcomes. “The trial is precluded from judging [hospital admissions], based on what is a reasonable size and duration to serve the public good here,” he said.

Hospital admissions and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30 000 people. The same is true of its ability to save lives or prevent transmission: the trials are not designed to find out.

Zaks said, “Would I like to know that this prevents mortality? Sure, because I believe it does. I just don’t think it’s feasible within the timeframe [of the trial]—too many would die waiting for the results before we ever knew that.”

Stopping transmission

What about Hotez’s second criterion, interrupting virus transmission, which some experts have argued¹⁷ should be the most important test in phase III studies?

“Our trial will not demonstrate prevention of transmission,” Zaks said, “because in order to do that you have to swab people twice a week for very long periods, and that becomes operationally untenable.”

He repeatedly emphasised these “operational realities” of running a vaccine trial. “Every trial design, especially phase III, is always a balancing act between different needs,” he said. “If you wanted to have an answer on an endpoint that happens at a frequency of one 10th or one fifth the frequency of the primary endpoint, you would need a trial that is either 5 or 10 times larger or you’d need a trial that is 5 or 10 times longer to collect those events. Neither of these, I think, are acceptable in the current public need for knowing expeditiously that a vaccine works.”

Zaks added, “A 30 000 [participant] trial is already a fairly large trial. If you’re asking for a 300 000 trial then you need to talk to the people who are paying for it, because now you’re talking about not a \$500m to \$1bn trial, you’re talking about something 10 times the size. And I think the public purse and operational capabilities and capacities we have are rightly spent not betting the farm on one vaccine but, as Operation Warp Speed [the US government’s covid-19 vaccine plan] is trying to do, making sure that we’re funding several vaccines in parallel.”

Debating endpoints

Still, it’s fair to say that most of the general public assumes that the whole point of the current trials, besides testing safety (box 1), is to see whether the vaccine can prevent bad outcomes. “How do you reconcile that?” *The BMJ* asked Zaks.

Box 1: Safety and side effects

History shows many examples of serious adverse events from vaccines brought to market in periods of enormous pressure and expectation. There were contaminated polio vaccines in 1955, cases of Guillain-Barré syndrome in recipients of flu vaccines in 1976, and narcolepsy linked to one brand of influenza vaccine in 2009.^{18 19}

“Finding severe rare adverse events will require the study of tens of thousands of patients, but this requirement will not be met by early adoption of a product that has not completed its full trial evaluation,” Harvard drug policy researchers Jerry Avorn and Aaron Kesselheim recently wrote in *JAMA*.²⁰

Covid-19 vaccine trials are currently designed to tabulate final efficacy results once 150 to 160 trial participants develop symptomatic covid-19—and most trials have specified at least one interim analysis allowing for the trials to end with even fewer data accrued.

Medscape’s Eric Topol has been a vocal critic of the trials’ many interim analyses. “These numbers seem totally out of line with what would be considered stopping rules,” he says. “I mean, you’re talking about giving a vaccine with any of these programmes to tens of millions of people. And you’re going to base that on 100 events?”⁸

Great uncertainty remains over how long a randomised trial of a vaccine will be allowed to proceed. If efficacy is declared, one possibility is that the thousands of volunteers who received a saline placebo would be offered the active vaccine, in effect ending the period of randomised follow-up. Such a move would have far reaching implications for our understanding of vaccines’ benefits and harms, rendering uncertain our knowledge of whether the vaccines can reduce the risk of serious covid-19 disease and precluding any further ability to compare adverse events in the experimental versus the placebo arm.

“It’ll be a decision we’ll have to take at that time. We have not committed one way or another,” Moderna’s Tal Zaks told *The BMJ*. “It will be a decision where FDA and NIH will also weigh in. And it will be probably a very difficult decision, because you will be weighing the benefit to the public in continuing to understand the longer term safety by keeping people on placebo and the expectation of the people who have received placebo to be crossed over now that it has been proved effective.”

“Very simply,” he replied. “Number one, we have a bad outcome as our endpoint. It’s covid-19 disease.” Moderna, like Pfizer and Janssen, has designed its study to detect a relative risk reduction of at least 30% in participants developing laboratory confirmed covid-19, consistent with FDA and international guidance.^{21 22}

Number two, Zaks pointed to influenza vaccines, saying they protect against severe disease better than mild disease. To Moderna, it’s the same for covid-19: if its vaccine is shown to reduce symptomatic covid-19, it will be confident it also protects against serious outcomes.

But the truth is that the science remains far from clear cut, even for influenza vaccines that have been used for decades. Although randomised trials have shown an effect in reducing the risk of symptomatic influenza, such trials have never been conducted in elderly people living in the community to see whether they save lives.

Only two placebo controlled trials in this population have ever been conducted, and neither was designed to detect any difference in hospital admissions or deaths.²³ Moreover, dramatic increases in use of influenza vaccines has not been associated with a decline in mortality (box 2).²⁶

Box 2: Not enrolling enough elderly people or minorities

A vaccine that has been proved to reduce the risk of symptomatic disease by a certain proportion should, you might think, reduce serious outcomes such as hospital admissions and deaths in equal proportion.

Peter Marks, an FDA official with responsibility over vaccine approvals, recently stated as much about influenza vaccination, which “only prevents flu in about half the people who get it. And yet that’s very important because that means that it leads to half as many deaths related to influenza each year.”²⁴

But when vaccines are not equally effective in all populations the theory breaks down.

If frail elderly people, who are understood to die in disproportionate numbers from both influenza²⁵ and covid-19, are not enrolled into vaccine trials in sufficient numbers to determine whether case numbers are reduced in this group, there can be little basis for assuming any benefit in terms of hospital admissions or mortality. Whatever reduction in cases is seen in the overall study population (most of which may be among healthy adults), this benefit may not apply to the frail elderly subpopulation, and few lives may be saved.

This is hard to evaluate in the current trials because there are large gaps in the types of people being enrolled in the phase III trials (table 1). Despite recruiting tens of thousands, only two trials are enrolling children less than 18 years old. All exclude immunocompromised people and pregnant or breastfeeding women, and though the trials are enrolling elderly people, few or perhaps none of the studies would seem to be designed to conclusively answer whether there is a benefit in this population, despite their obvious vulnerability to covid-19.

"Adults over 65 will be an important subgroup that we will be looking at," Moderna's Zaks told *The BMJ*. "That said . . . any given study is powered for its primary endpoint—in our case covid-19 disease irrespective of age."

Al Sommer, dean emeritus of the Johns Hopkins School of Public Health, told *The BMJ*, "If they have not powered for evidence of benefit in the elderly, I would find that a significant, unfortunate shortcoming." He emphasised the need for "innovative follow-up studies that will enable us to better determine the direct level of protection immunisation has on the young and, separately, the elderly, in addition to those at the highest risk of severe disease and hospitalisation."

One view is that trial data should be there for all target populations. "If we don't have adequate data in the greater than 65 year old group, then the greater than 65 year old person shouldn't get this vaccine, which would be a shame because they're the ones who are most likely to die from this infection," said vaccinologist Paul Offit.⁸ "We have to generate those data," he said. "I can't see how anybody—the Data and Safety Monitoring Board or the FDA Vaccine Advisory Committee, or FDA decision-makers—would ever allow a vaccine to be recommended for that group without having adequate data."

"I feel the same way about minorities," Offit added. "You can't convince minority populations to get this vaccine unless they are represented in these trials. Otherwise, they're going to feel like they're guinea pigs, and understandably so."

Competing interests: I co-wrote an op-ed on this topic with Eric Topol, who is quoted in this article, I have been pursuing the public release of vaccine trial protocols, and I co-signed an open letter to the FDA calling for independence and transparency in covid-19 vaccine related decision making.

Provenance and peer review: Commissioned; externally peer reviewed.

Sarah Tanveer helped research the design of studies and identify quotations, and Ulrich Keil provided comments on an early draft of this article.

- Shah A, Marks PW, Hahn SM. Unwavering Regulatory Safeguards for COVID-19 Vaccines. *JAMA* 2020. doi: 10.1001/jama.2020.15725. PMID: 32766736
- Cavazzoni P, Marks P, Mayne S, et al. Senior FDA career executives: We're following the science to protect public health in pandemic. *USA Today*. 2020 Sep 10. <https://www.usatoday.com/story/opinion/2020/09/10/sound-science-to-meet-covid-challenges-fda-career-officials-col-umn/5756948002>.
- Office of the Commissioner. The FDA's Oversight of Vaccines is Vital to Public Health. 2020. <https://www.fda.gov/news-events/fda-voices/fdas-scientific-and-regulatory-oversight-vaccines-vital-public-health>
- Hahn S. Remarks on the vaccine review process. 2020. <https://www.fda.gov/news-events/speeches-fda-officials/dr-hahns-remarks-national-consumer-league-vaccine-review-process-09292020>.
- Sanofi. Biopharma leaders unite to stand with science. Sep 2020. <https://www.news.sanofi.us/2020-09-08-Biopharma-leaders-unite-to-stand-with-science>.
- Palca J. What a nasal spray vaccine against covid-19 might do even better than a shot. *NPR*. 2020 Aug 28. <https://www.npr.org/sections/health-shots/2020/08/28/906797539/what-a-nasal-spray-vaccine-against-covid-19-might-do-even-better-than-a-shot>.
- Curwen T. Those coronavirus vaccines leading the race? Don't ditch the masks quite yet. *Yahoo Finance*. 2020. <https://finance.yahoo.com/news/those-coronavirus-vaccines-leading-race-120006184.html>.
- Topol EJ. Paul Offit's biggest concern about covid vaccines. 2020. <https://www.med-scape.com/viewarticle/936937>.
- Moderna. Clinical study protocol: A phase 3, randomized, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine in adults aged 18 years and older [protocol No mRNA-1273-P301]. 2020. <http://web.archive.org/web/20201018173405/https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf>.
- Pfizer. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001. 2020. https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf.
- AstraZeneca. Clinical Study Protocol - Amendment 2 AZD1222- D8110C00001. 2020. https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf.
- Janssen Vaccines & Prevention BV. VAC31518 (JNJ-78436735) clinical protocol VAC31518COV3001 amendment 1. 2020. <https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol>.
- CDC. Coronavirus disease 2019 (COVID-19). 2020. <http://web.archive.org/web/20200709001525/https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>.
- CDC. What to do if you are sick. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html>.
- Moderna advances late-stage development of its vaccine (mRNA-1273) against covid-19. <https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273>.
- National Institutes of Health. Phase 3 clinical trial of investigational vaccine for COVID-19 begins. 2020. <https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins>.
- Finn A, Malley R. A vaccine that stops covid-19 won't be enough. *New York Times*. 2020 Aug 24. <https://www.nytimes.com/2020/08/24/opinion/coronavirus-vaccine-prevention.html>.
- Trojan B, Oshinsky D, Caplan A. Adverse consequences of rushing a SARS-CoV-2 vaccine: implications for public trust. *JAMA* 2020;323:1. doi: 10.1001/jama.2020.8917. PMID: 32453392
- Doshi P. Pandemrix vaccine: why was the public not told of early warning signs? *BMJ* 2018;362:doi: 10.1136/bmj.k3948.
- Avorn J, Kesselheim A. Regulatory decision-making on covid-19 vaccines during a public health emergency. *JAMA* 2020. doi: 10.1001/jama.2020.17101. PMID: 32870268
- International Coalition of Medicines Regulatory Authorities. ICMRA SARS-CoV-2 Vaccines Workshop #2 - Summary. 2020. www.icmra.info/drupal/en/news/22june2020/summary.
- Food and Drug Administration. Development and licensure of vaccines to prevent covid-19: guidance for industry. 2020. <https://www.fda.gov/media/139638/download>.
- Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. *JAMA* 1994;272:5. doi: 10.1001/jama.1994.03520210045030 PMID: 7966893
- Office of the Commissioner. FDA Insight. Vaccines (Base) 2020;COVID-19. <https://www.fda.gov/news-events/fda-insight/fda-insight-vaccines-covid-19-part-1>.
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012;12:44. doi: 10.1016/S1473-3099(11)70295-X PMID: 22032844
- Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. *Arch Intern Med* 2005;165:72. doi: 10.1001/archinte.165.3.265 PMID: 15710788

This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.